Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
AstraZeneca to acquire Amolyt Pharma for up to US$1.05bn
Under the agreement set to close in Q3/2024, AstraZeneca will acquire Amolyt Pharma for US$800m upfront and potential milestone payments of US$250m....
Roche presents restistance-breaking antibiotic
Antibiotic resistance has become an urgent threat to global public health in recent decades....
Pacifico Biolabs raises US$3.3m in pre-seed round
Riding the wave of mushroom mycelium-based foods, which are advertised as a climate- and animal-friendly alternative to meat, Pacifico Biolabs GmbH...
Novartis AG to buy immunology specialist Calypso Biotech BV
Upon closure, the US$425m take-over of the Amsterdam-headquartered Calypso Biotech NV, would give Novartis AG full commercialisation rights to...
LimmaTech Biologics acquires licence option for AbVacc vaccine LBT-SA7
Under the agreement, Schlieren-based LimmaTech Biologics AG receives the exclusive rights from Abbvacc Inc, a recent spin-out from Integrated...
EU parliament backs deregulation of New Genome Techniques
With the MEPs' approval of the amendments to the European Commission's draft legislation, the way is now clear for a regulation that distinguishes...